Substance P modulates NMDA responses and causes long-term protein synthesis-dependent modulation of the lamprey locomotor network.
Tachykinin immunoreactivity is found in a ventromedial spinal plexus in the lamprey. Neurons in this plexus project bilaterally and are thus in a position to modulate locomotor networks on both sides of the spinal cord. We have examined the effects of the tachykinin substance P on NMDA-evoked locomotor activity. Brief (10 min) application of tachykinin neuropeptides results in a prolonged concentration-dependent (>24 hr) modulation of locomotor activity, shown by the increased burst frequency and more regular burst activity. These effects are blocked by the tachykinin antagonist spantide II. There are at least two phases to the burst frequency modulation. An initial phase (approximately 2 hr) is associated with the protein kinase C-dependent potentiation of cellular responses to NMDA. The long-lasting phase (>2 hr) appears to be protein synthesis-dependent, with protein synthesis inhibitors causing the increased burst frequency to recover after washing for 2-3 hr. The modulation of the burst regularity is caused by a separate effect of tachykinins, because unlike the burst frequency modulation it does not require the modulation of NMDA receptors for its induction and is blocked by H8, an inhibitor of cAMP- and cGMP-dependent protein kinases. The effects of substance P were mimicked by the dopamine D2 receptor antagonist eticlopride. The effects of eticlopride were blocked by the tachykinin antagonist spantide II, suggesting that eticlopride may endogenously release tachykinins. Because locomotor activity in vitro corresponds to that during swimming in intact animals, we suggest that endogenously released tachykinins will result in prolonged modulation of locomotor behavior.
Parker
D
D
The Nobel Institute for Neurophysiology, Department of Neuroscience, Karolinska Institute, S 17177, Stockholm, Sweden.
Zhang
W
W
Grillner
S
S
D000818:Animals; D065127:Dopamine D2 Receptor Antagonists; D004594:Electrophysiology; D005998:Glycine / Q000378:metabolism; D007798:Lampreys / Q000502:physiology*; D008274:Magnesium / Q000494:pharmacology; D009043:Motor Activity / Q000502:physiology*; D016202:N-Methylaspartate / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D009415:Nerve Net / Q000502:physiology*; D009419:Nerve Tissue Proteins / Q000096:biosynthesis*; D011493:Protein Kinase C / Q000502:physiology; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology; D016194:Receptors, N-Methyl-D-Aspartate / Q000502:physiology; D015290:Second Messenger Systems / Q000502:physiology; D013373:Substance P / Q000494:pharmacology / Q000502:physiology*; D015320:Tachykinins / Q000037:antagonists & inhibitors / Q000494:pharmacology; D013997:Time Factors
D065127:Dopamine D2 Receptor Antagonists; D009419:Nerve Tissue Proteins; D011500:Protein Synthesis Inhibitors; D016194:Receptors, N-Methyl-D-Aspartate; D015320:Tachykinins; D013373:Substance P; D016202:N-Methylaspartate; D011493:Protein Kinase C; D008274:Magnesium; D005998:Glycine